麻性肥胖现象型指数 (SOPi):一个基于人口的研究
Elizabeth Benz1,2, Alexandre Pinel1, Christelle Guillet1
1Human Nutrition Unit, Clermont Auvergne University, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France.
Journal of cachexia, sarcopenia and muscle
|October 16, 2025
概括
一个新的 Sarcopenic Obesity Prognostic Index (SOPi) 预测了过早死亡的风险. 这种持续的测量可以识别与sarcopenic obesity (SO) 和其进展相关的因素,有助于早期检测和预防.
科学领域:
- 老年学是一门学科.
- 代谢健康 代谢健康
- 身体组成分析 身体成分分析
背景情况:
- 麻性肥胖症 (SO) 结合了高体脂与低肌肉质量/功能,增加了死亡风险.
- 目前的SO诊断方法是二进制的,限制了疾病进展的跟踪.
- 早期检测和监测对于管理SO和预防不良结果至关重要.
研究的目的:
- 开发一个连续的 Sarcopenic Obesity Prognostic Index (SOPi),整合肌肉功能和身体组成.
- 评估SOPi与全因死亡率之间的关联.
- 确定与基线SOPi相关的因素,并跟踪随时间的变化.
主要方法:
- 利用了来自鹿特丹研究的数据,包括手握强度 (HGS),尾瘦肉量指数 (ALM/kg) 和身体脂肪百分比 (BF%).
- 使用特定性别方程计算的SOPi集成z-score的BF%,HGS和ALM/kg.
- 采用考克斯回归和线性混合效应模型来分析死亡风险,相关因素和SOPi变化.
主要成果:
- 每个SD增加的SOPi与10%更高的过早死亡风险相关 (HR=1.10).
- 包括减少体力活动,胰岛素抵抗和炎症在内的13个因素与高SOPi有关.
- 患有肥胖症和身体活动低或胰岛素抵抗等因素的参与者显示SOPi增加速度更快.
结论:
- SOPi有效地预测过早死亡,并确定相关的风险因素,特别是在风险较高的人群中.
- 在特定的表型中,SOPi表现出更高的值和更快的进展.
- 该SOPi作为SO风险评估和预防策略的有价值的预后指标.
相关概念视频
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
01:29Bias in Epidemiological Studies
1.3K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.3K
01:21Drug Dosing: Obese Patients
218
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
218